CHIP Vaccine Program

Pursuant to New York State Finance Law §163.10(b), the New York State Department of (DOH) is presenting the following summary of relevant circumstances and substantial reasons why a competitive procurement was not feasible. The New York State Office of the State Comptroller’s Bureau of Contracts on 12/3/25 approved an exemption from giving notice in the New York State Contract Reporter for pediatric vaccine purchases from multiple manufacturers.

Due to the specific circumstances of this procurement, a competitive procurement was not feasible in this instance. Eighteen (18) month single source purchase authorizations will be established with the following manufacturers to provide pediatric vaccines while a competitive procurement is completed to ensure that critical pediatric vaccines remain available to CHIP vaccine recipients:

  • AstraZeneca Pharmaceuticals LP
    BAVARIAN NORDIC
    DYNAVAX TECHNOLOGIES CORPORATION
    GlaxoSmithKline Holdings (Americas)
    MERCK SHARP & DOHME
    Moderna TX
    PFIZER
    Sanofi Pasteur Inc.
    Seqirus USA Inc
Procurement / Program Name CHIP Vaccine Program
Contractor Name(s) AstraZeneca Pharmaceuticals LP
BAVARIAN NORDIC
DYNAVAX TECHNOLOGIES CORPORATION
GlaxoSmithKline Holdings (Americas)
MERCK SHARP & DOHME
Moderna TX
PFIZER
Sanofi Pasteur Inc.
Seqirus USA Inc
Contract Period 10/1/25-3/31/27
Contract Number PA42665, PA42666, PA42667, PA42668, PA42669,
PA42670, PA42671, PA42672, PA42673